Introduction
The fibroblast growth factor (FGF) family consists of at least 18 structurally related proteins with diverse roles in physiological and pathological processes, such as cell growth, differentiation, angiogenesis, wound healing, and tumor development. FGFs exert their biological effects by binding to and activating a family of type I transmembrane tyrosine kinase receptors known as FGF receptors (FGFRs). Upon ligand binding, FGFRs dimerize and undergo autophosphorylation, initiating downstream signaling cascades. Currently, four distinct genes encoding highly similar FGFRs (FGFR1-4) have been identified. All four FGFR genes encode proteins with a conserved structure, including an N-terminal signal peptide, three immunoglobulin (Ig)-like domains, an acidic region located between IgI and IgII domains, a transmembrane domain, and a split tyrosine kinase domain. Alternative splicing of FGFR1-3 mRNAs results in the generation of multiple receptor isoforms. One common splicing event affects FGFR1 and FGFR2, leading to isoforms containing either all three Ig domains (designated as the 'a' isoform) or only IgII and IgIII domains (designated as the 'b' isoform). In contrast, only the 'a' isoform has been observed for FGFR3 and FGFR4. Further splicing events involving FGFR1-3 occur in the C-terminal half of the IgIII domain, which is encoded by two mutually exclusive exons. These events generate FGFRs with alternative IgIII domains (IIIb and IIIc). Notably, a secreted FGFR1 isoform called IIIa has been reported, consisting of the N-terminal half of the IgIII domain and some intronic sequences. This isoform functions as an FGF-binding protein. Mutations in FGFR1-3 genes have been linked to birth defects characterized by craniosynostosis. Ongoing research aims to elucidate the intricate expression patterns of these receptors and their specific interactions with various FGF ligands.
Description
Soluble FGFR-4a (IIIc) Fc Chimera Human Recombinant is a genetically engineered protein comprising the extracellular domain of human FGFR-4a (IIIc) fused to the Fc region of human IgG1. This chimeric protein is produced in baculovirus-infected insect cells, resulting in a heterodimeric glycoprotein with an approximate molecular weight of 170 kDa. The purification process involves proprietary chromatographic techniques to ensure high purity. Key features: - Extracellular domain of human FGFR-4a (IIIc) fused to human IgG1 Fc. - Produced in baculovirus expression system. - Heterodimeric glycoprotein with a molecular weight of approximately 170 kDa. - Purified using proprietary chromatographic methods.
Physical Appearance
White powder, lyophilized and sterile.
Formulation
CD334 was lyophilized from a sterile solution at a concentration of 1 mg/mL, without any additional additives.
Solubility
To reconstitute the lyophilized FGFR-4, it is recommended to dissolve it in sterile PBS at a minimum concentration of 100 µg/mL. The reconstituted solution can be further diluted in other aqueous solutions as needed.
Stability
Lyophilized FGFR4 remains stable at room temperature for up to 3 weeks. However, for long-term storage, it is recommended to store it desiccated at a temperature below -18°C. After reconstitution, FGFR4 should be stored at 4°C for 2-7 days. For extended storage, it is advisable to store it at temperatures below -18°C. To ensure optimal stability during long-term storage, it is recommended to add a carrier protein (0.1% HSA or BSA) to the reconstituted solution. Avoid repeated freeze-thaw cycles to maintain protein integrity.
Purity
The purity of FGFR-4 is greater than 90%, as determined by the following methods: (a) Reverse-phase high-performance liquid chromatography (RP-HPLC) analysis. (b) Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) analysis.
Biological Activity
The biological activity of FGFR-4 is assessed by its ability to inhibit human acidic fibroblast growth factor (FGF-acidic)-induced proliferation in R1 cells. The half-maximal effective concentration (ED50) for this inhibitory effect typically falls within the range of 15.0-30.0 ng/mL.
Synonyms
Fibroblast Growth Factor Receptor 4, EC 2.7.10.1, JTK2, TKF, Tyrosine Kinase Related To Fibroblast Growth Factor Receptor, Hydroxyaryl-Protein Kinase, Protein-Tyrosine Kinase, Tyrosylprotein Kinase, CD334 Antigen, EC 2.7.10, FGFR-4, CD334, FGFR4.
